Belgrade, September 7, 2021 – During the first seven months of this year, Galenika achieved a significant expansion of its product portfolio, growth in Serbia and regional markets, and further modernization of operations. Galenika shows constant growth in all segments of its business in 2021. In the period from January to July, Galenika achieved a 16% increase in production compared to the same period last year. Since the beginning of the year, the company has registered as many as 12 new products in Serbia, while 11 products have been launched on the market so far. Galenika records an increase in sales in the region, and by the end of July 2021, five products have been launched on the markets of Bosnia and Herzegovina, Montenegro and Northern Macedonia, and another 9 are planned to be launched by the end of the year. In the EU market, Galenika has registered one product, and the registration of another 20 products is planned. Galenika’s Institute for Research and Development, in strategic partnership with its sister company from Brazil – EMS, is working on the technology transfer of five products from the newer generation of generic drugs.
In the period January-July 2021, Galenika achieved an increase in sales by 13 percent compared to the same period last year, which further strengthened the company in the stable second position in terms of share in the pharmaceutical market of Serbia. Exports to the countries of the region (Bosnia and Herzegovina, Montenegro, North Macedonia) increased by as much as 51 percent, while sales on international markets outside the region (Europe, Middle East, Africa) is more than doubled.
“Galenika is a company that looks to the future and our innovative processes are an important success. We continue to plan and adapt, to make team efforts and do what we do best, while remaining devoted to people and dedicated to health. We are strategically focused on innovations in the company and a product portfolio for the benefit of consumers. As a modern and stable company with a great team and an innovative way of thinking, Galenika will become even bigger, with a strong regional presence”, said Ricardo Vian Marques, General Manager of Galenika.
In June this year, Galenika became the winner of the prestigious SAP Quality Award for the region of Central and Eastern Europe, for the project of innovative business transformation through the implementation of the most modern business management system – SAP S / 4HANA Cloud. Additionally, in the field of digitalization of business processes, as the first pharmaceutical company in Serbia, Galenika started with the introduction of advanced user interface Fiori UX, which enables easier and faster work with increased efficiency, productivity and user mobility with “work anytime, anywhere” approach.
Galenika continues with ambitious plans when for expanding its product portfolio. In addition to the 12 registered, the registration of 18 new products for the Serbian market is in progress, and by the end of the year it is planned to submit a request for registration of 8 more products.